Pre-clinical strategies and safety issues in developing therapeutic monoclonal antibodies

New Biotechnology

Volumn 28, Issue 5, 2011, Pages 481-488

  Chamberlain, Paul ^a  

^a BioLOGICA Consulting   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN SUBJECTS; MEDICINAL PRODUCTS; PRE-CLINICAL; PREDICTIVE VALUES; PRODUCT CLASS; SAFETY EVALUATIONS; SAFETY ISSUES; TEST SYSTEMS; THERAPEUTIC MONOCLONAL ANTIBODIES;

MONOCLONAL ANTIBODIES;

MONOCLONAL ANTIBODY;

CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL FEATURE; DRUG SAFETY; GENOTOXICITY; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK; RISK FACTOR; TAXONOMY;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG TOXICITY; HUMANS; RISK ASSESSMENT; RISK FACTORS;

EID: 80052555040     PISSN: 18716784     EISSN: 18764347     Source Type: Journal    
DOI: 10.1016/j.nbt.2011.03.017     Document Type: Review

References (36)

1. EMEA/CHMP Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products 2007.
2. Snodin D.J., Ryle P.R. Understanding and applying regulatory guidance on the nonclinical development of biotechnology-derived pharmaceuticals. Biodrugs 2006, 20:25-52.
3. EU Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of Member States regarding the protection of animals used for experimental and other scientific purposes.
4. Descotes J. Immunotoxicity of monoclonal antibodies. mAbs 2009, 1:104-111.
5. Hansel T.T., et al. The safety and side effects of monoclonal antibodies. Nat. Rev. Drug Discov. 2010, 9:325-338.
6. Brennan F.R., et al. Safety and immunotoxicity assessment of immunomodulatory monoclonal antibodies. mAbs 2010, 2:233-255.
7. Tabrizi M.A., Roskos L.K. Preclinical and clinical safety of monoclonal antibodies. Drug Discov. Today 2007, 12:540-547.
8. Isaacs J.D. From bench to bedside: discovering rules for antibody design, and improving serotherapy with monoclonal antibodies. Rheumatology 2001, 40:724-738.
9. Schneider C.K., et al. TGN1412 - a regulator's perspective. Nat. Biotechnol. 2006, 24:493-496.
10. ICH Harmonized Tripartite Guideline S6. (1997) Preclinical safety evaluation of biotechnology-derived pharmaceuticals.
11. FDA CBER. (1997) Points to consider in the manufacture and testing of monoclonal antibody products for human use.
12. Addendum to ICH S6. (2009) Preclinical safety evaluation of biotechnology-derived pharmaceuticals, S6 (R1), Step 2.
13. Suntharalingam G., et al. Cytokine storm in a Phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 2006, 355:1018-1028.
14. Chapman K., et al. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nat. Rev. Drug Discov. 2007, 6:120-126.
15. Reddy M.P., et al. Elimination of Fc receptor-dependent effector functions of a modified IgG4 monoclonal antibody to human CD4. J. Immunol. 2000, 164:1925-1933.
16. Chung C.H., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-α-1,3-galactose. N. Engl. J. Med. 2008, 358:1109-1117.
17. Srinivasappa J., et al. Molecular mimicry: frequency of reactivity of monoclonal antiviral antibodies with normal tissues. J. Virol. 1986, 57:397-401.
18. Bugelski P.J., et al. Monoclonal antibody-induced cytokine-release syndrome. Expert Rev. Clin. Immunol. 2009, 5:499-521.
19. Findley L., et al. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412. J. Immunol. Methods 2010, 352:1-12.
20. Tawara T., et al. Complement activation plays a key role in antibody-induced infusion toxicity in monkeys and rats. J. Immunol. 2008, 180:2294-2298.
21. Vallhonrat H., et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 1999, 67:253-258.
22. Bindon C.I., et al. Human monoclonal IgG isotypes differ in complement activation function at the level of C4 as well as C1q. J. Exp. Med. 1988, 168:127-142.
23. Guo R.F., Ward P.A. Role of C5a in inflammatory responses. Annu. Rev. Immunol. 2005, 23:821-852.
24. Piddleston S., et al. Clin. Exp. Immunol. 1991, 83:245-250.
25. Subramanyman M., et al. Selection of relevant species. Preclinical Safety Evaluation of Biopharmaceuticals: A Science-based Approach to Facilitating Clinical Trials 2008, 181-205. Wiley. J.A. Cavagnaro (Ed.).
26. FDA CDER Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers 2005.
27. ICH Harmonized Tripartite Guideline M3 (R2). (2009) Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals.
28. Deng R., et al. Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data - What have we learned?. mAbs 2011, 3:1-6.
29. Ghaderi D., et al. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins. Nat. Biotechnol. 2010, 28:863-867.
30. Hod E.A., et al. Hypothesis: haemolytic transfusion reactions represent an alternative type of anaphylaxis. Int. J. Clin. Exp. Pathol. 2009, 2:71-82.
31. Ponce R., et al. Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies. Regul. Toxicol. Pharmacol. 2009, 54:164-182.
32. Clarke J., et al. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody. Regul. Toxicol. Pharmacol. 2004, 40:219-226.
33. Bugelski P.J., et al. Preclinical development of keliximab, a primatized anti-CD4 monoclonal antibody, in human CD4 transgenic mice: characterization of the model and safety studies. Hum. Exp. Toxicol. 2000, 19:230-243.
34. Kosterink J.G.W., et al. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. J. Immunol. 2007, 179:1362-1368.
35. Legrand N., et al. Transient accumulation of human mature thymocytes and regulatory T cells with CD28 superagonist in " human immune system" Rag2-/-γc-/- mice. Blood 2006, 108:238-245.
36. Visich J., Ponce R. Science and judgement in establishing a safe starting dose for first-in-human trials of biopharmaceuticals. Preclinical Safety Evaluation of Biopharmaceuticals: A Science-based Approach to Facilitating Clinical Trials 2008, 971-984. Wiley. J.A. Cavagnaro (Ed.).